In our previous P01 project we examined the relationship between the expression of CXCR4 by metastatic prostate cancers (PCa) and their bone homing behavior. From these studies we acquired data that suggest that not only do PCa's use the CXCR4/SDF-1 pathway to home to bone - but there is a strong likelihood they use the hematopoietic stem cell (HSC) 'niche' itself to colonize the skeleton. Here our work in this field has demonstrated that annexin II (Anxa2) expressed by osteoblasts (08s) and plays a critical role in niche selection. Among the most compelling mechanisms to account for these observations are either that (i) Anxa2 acts as an adhesion ligand, and (ii) when HSCs bind to Anxa2, quiescence is induced. Our preliminary data strongly suggests that similar molecular mechanisms are functional in metastatic PCa in the marrow. Hypothesis: Metastatic pea parasitizes the 'niche' as a molecular mechanism for osteotropism. The following aims are proposed: (1) Define the location of the metastatic 'niche' and its interactions with primary tumors. Sub hypothesis: Molecular cross talk between a primary (1 ) tumor and the premetastatic 'niche' helps to govern the homing of metastatic PCa. We will explore the localization of PCa metastatic niche in bone. We will determine where PCa cells injected by an (i) i.c. route localize in marrow and (ii) whether the same niche is seeded by tumors established in our orthotopic metastasis model. (iii) Determine if the expression of CXCR4/RDC1 and Anxa2r is different when PCa cells are in the 'niche'. (2) Determine whether expression of SDF-1 and Anxa2 by the 'niche' is essential for metastasis. Sub hypothesis: Co-opting the HSC niche is essential for metastasis. In this aim we will determine if the expression of (2A) SDF-1, (28) Anxa2 are essential for homing/lodging of PCa in bone. PCa cells are implanted in vivo orthotopically and 'shed' or disseminated cells are tracked by QPCR. This assay allows us to identify and explore extremely early events. (3) Define the interaction(s) of PCa and the 'niche'. Sub hypothesis: PCa use the HSC niche to establish a 'foot hold' in the marrow. We will; (3A) define the role that SDF-1 signaling pathways, (38) Anxa2 and its receptor (Anxa2r) playas molecular mechanisms for 'niche' parasitism once metastatic PCa cells have entered the niche. In our final sub aim, we will link the previous studies to (3C) determine if Anxa2/Anxa2r signaling facilitates PCa growth in bone via SDF-1.

Public Health Relevance

Growth of prostate cancer in the bone is a common and serious late event of prostate cancer. Our proposed work will help define why prostate cancer can thrive in the bone including identifying key signals used for the establishment of prostate cancer metastases in bone. This work will help lay the foundations for evaluating therapeutic interventions.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Lee, Eunsohl; Wang, Jingcheng; Jung, Younghun et al. (2018) Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer. J Cell Biochem 119:3697-3705
van der Toom, Emma E; Axelrod, Haley D; de la Rosette, Jean J et al. (2018) Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol :
Roca, Hernan; McCauley, Laurie K (2018) Efferocytosis and prostate cancer skeletal metastasis: implications for intervention. Oncoscience 5:174-176
Chalfin, Heather J; Glavaris, Stephanie A; Malihi, Paymaneh D et al. (2018) Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol 199:1494-1501
Axelrod, Haley D; Pienta, Kenneth J; Valkenburg, Kenneth C (2018) Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells. Biol Proced Online 20:13

Showing the most recent 10 out of 228 publications